3 unknown. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 3 |
Follow Neoplasm Malignant: new trials by email Literature Review of Neoplasm Malignant trials Research Report on Neoplasm Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 First-in-human Study of JS014 JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody, Pembrolizumab - anti-PD-1 antibody - Neoplasm Malignant, Neoplasm, Experimental | Phase 1 | Unknown | Anwita Biosciences | 60 | 2022-02-28 | 2023-09-06 |
| A Study of PSB205 in Subjects With Advanced Solid Tumors PSB205 - Neoplasm Malignant | Phase 1 | Unknown | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 64 | 2019-07-05 | 2020-11-25 |
| Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors SHR9146+SHR-1210, SHR9146+SHR-1210+Apatinib - Tumor, Solid, Cancer, Metastatic | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 23 | 2018-11-20 | 2022-11-04 |
Neoplasms (3) · Lymphoma (1) · Neoplasm Metastasis (1) · Neoplasms, Experimental (1)
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms by Histologic Type (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Interleukin-21 (1) · pembrolizumab (1)
Anwita Biosciences (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Qilu Puget Sound Biotherapeutics (dba Sound Biologics) (1)
China (1) · Taiwan (1) · United States (1)
TJ Chiou, MD (1) · Ying Cheng, Prof. (1)